Safety and Efficacy of Synchronized Cardiac Support (SCS) Versus Continuous Flow VA-ECMO in Cardiogenic Shock (PulseSE)
Safety and Efficacy of Synchronized Cardiac Support (SCS) Versus Continuous Flow VA-ECMO in Cardiogenic Shock: A Randomized-Controlled Pilot Study
This study aims to investigate the efficacy of the Synchronized Cardiac Support treatment with the Novalung ultimate kit SCS in patients with cardiogenic shock in comparison with patients treated with continuous flow VA-ECMO
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The current study hypothesizes that SCS treatment with the Novalung ultimate kit SCS provides sufficient cardiocirculatory support compared with continuous flow VA-ECMO Patients with cardiogenic shock, requiring a VA-ECMO for circulatory stabilization will be randomized 1:1 either in the investigational group receiving Synchronized Cardiac Support treatment or continuous VA-ECMO treatment as control group.
SCS describes an electrocardiogram (ECG)-triggered pulsatile VA-ECMO based on R-wave detection. During diastole the pump speed and thus the blood flow is increased and during systole the pump flow is set to a relative minimum. This provides a mechanical circulatory support pulse with increased oxygenated blood supply during diastole. The SCS treatment will start as soon the heart rate of the patient is below 110 bpm.
SCS is used in a standard VA-ECMO configuration by two femoral single vessel cannulas according to local practice of study site The duration of the treatment can be up to 14 days.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Fiona Bellando
- 電話番号:+49 6172 8868776
- メール:fiona.bellando@freseniusmedicalcare.com
研究場所
-
-
-
Madrid、スペイン、28046
- Hospital Universitario La Paz
-
コンタクト:
- Sandra Ofelia Rosillo Rodriguez, Dr. med.
- メール:sorrph17@gmail.com
-
-
-
-
-
Prague、チェコ、150 06
- Motol University Hospital
-
コンタクト:
- Petr Ostadal, Prof. MD
- メール:petr.ostadal@lfmotol.cuni.cz
-
Prague、チェコ、128 08
- General University Hospital Prague
-
コンタクト:
- Jan Bělohlávek, Prof. MD
- メール:jan.belohlavek@vfn.cz
-
-
-
-
-
Essen、ドイツ、45138
- Elisabeth-Krankenhaus Essen GmbH
-
コンタクト:
- Voigt Ingo, Dr med
- メール:I.Voigt@contilia.de
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Given the exploratory nature of this randomized study, no formal sample size calculation for between-group comparisons was performed.
Assuming that about 20% of the patients will not provide serum lactate levels at 8 hours after the start of SCS treatment in the Pulse SE study, a total of 50 patients will be enrolled, with 25 patients per treatment group.
This sample size is considered adequate to allow descriptive and exploratory comparisons within and between treatment groups and to estimate effect sizes for the primary and secondary endpoints which will inform the design and sample size planning of future confirmatory studies.
The patients will be enrolled in 4 study centres across Europe.
Inclusion criteria:
-
Informed consent signed and dated by study patient/legal representative or investigator/authorized physician
-
Minimum age of 18 years
-
Patients in cardiogenic shock, defined as SCAI C OR D, with evidence of hemodynamic compromise and hypoperfusion:
-
Hemodynamic compromise (low cardiac output and elevated filling pressures):
- Cardiac index < 2.2 l/min/m2 (invasive or non-invasive measurement)
- Central venous pressure > 7 mmHg OR pulmonary artery occlusion pressure > 12 mmHg OR left-ventricular end-diastolic pressure ˃ 12 mmHg OR B-lines on lung ultrasound
-
Hypoperfusion:
- Lactate ≥ 2 mmol/L OR SvO2 < 65% OR capillary refill time > 3 s OR pCO2 Gap > 0.8 kPa (>6 mmHg)
Exclusion criteria:
- In case of female patients: pregnancy or lactation period (if patient is ≥ 55 years old or have been surgically sterilized, a negative pregnancy test is not required)
- Participation in an interventional clinical study during the preceding 30 days
- Previous participation in the same study
- Age > 75 years
- Out of hospital cardiac arrest with return of spontaneous circulation (ROSC) > 30 min OR non-witnessed cardiac arrest or no flow time > 5 min
- Non-cardiogenic causes of shock (sepsis, hypovolemia, etc.)
- Bradycardia or tachycardia as a cause of shock
- Fever (Body temperature > 38.0 °C) or other evidence of sepsis
- Onset of cardiogenic shock > 4 h before enrolment
- Lactate > 16 mmol/L
- Severe peripheral arterial occlusive disease precluding insertion of femoral arterial or venous catheters
- Contraindications for anticoagulation
- Planned use of primary unloading or venting devices at randomization (e.g. Impella or IABP)
- Contraindication for VA-ECMO, e.g. severe aortic regurgitation, aortic dissection, limited life expectation
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:SCS Group
Investigational group receiving Synchronized Cardiac Support treatment |
Patients receiving Synchronized Cardiac Support (SCS) treatment with the Novalung ultimate kit SCS and the Xenios 2.0 - Pulsatile flow |
|
他の:Control Group VA-ECMO treatment
Control group receiving continous VA-ECMO treatment |
Patients receiving continuous flow VA-ECMO with the Novalung ultimate kit SCS and the Xenios 2.0 (Standard of care) |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cardiocirculatory stabilization and end-organ perfusion
時間枠:Baseline and during the ECMO treatment up to 7 days
|
Lactate clearance at 8 hours after randomization between SCS treatment and continuous flow VA-ECMO using the Novalung ultimate kit SCS will be assessed in an exploratory analysis via venous blood gas analysis (BGA) |
Baseline and during the ECMO treatment up to 7 days
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Performance objective - Cardiocirculation
時間枠:Baseline and during the ECMO treatment up to 7 days
|
Improvement and maintenance of patients' cardiocirculation (= cardiocirculatory stabilization). |
Baseline and during the ECMO treatment up to 7 days
|
|
Performance objective - Cardiac Output
時間枠:Baseline and during the ECMO treatment up to 7 days
|
Cardiac output measured using a pulmonary artery catheter (L/min) |
Baseline and during the ECMO treatment up to 7 days
|
|
Performance objective - organ perfusion
時間枠:Baseline and during the ECMO treatment up to 7 days
|
Improvement of end-organ perfusion |
Baseline and during the ECMO treatment up to 7 days
|
|
Blood gas analysis
時間枠:Baseline and during the ECMO treatment up to 7 days
|
Assessment of blood gas parameters by arterial blood gas analysis |
Baseline and during the ECMO treatment up to 7 days
|
|
ECLS performance - blood flow
時間枠:Baseline and during the ECMO treatment up to 7 days
|
Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): Maintenance of blood flow (L/min) |
Baseline and during the ECMO treatment up to 7 days
|
|
ECLS performance - Pump speed
時間枠:Baseline and during the ECMO treatment up to 7 days
|
Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): pump speed (rpm) |
Baseline and during the ECMO treatment up to 7 days
|
|
ECLS performance - Circuit pressures
時間枠:Baseline and during the ECMO treatment up to 7 days
|
Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): Circuit pressures (mmHg) |
Baseline and during the ECMO treatment up to 7 days
|
|
Safety objectives
時間枠:Baseline and during the ECMO treatment up to 7 days
|
Assessment of the safety of the SCS treatment with the Novalung ultimate kit SCS in patients with cardiogenic shock in comparison with patients treated with continuous flow VA-ECMO |
Baseline and during the ECMO treatment up to 7 days
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Ingo Voigt, Dr. med.、Elisabeth-Krankenhaus Essen
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- CS-SCS-02-EU
- CIV-26-06-058894 (その他の識別子:Eudamed-ID)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。